Abstract. Vascular endothelial growth inhibitor (VEGI) has been associated with tumor-related vasculature in certain malignancies. However, its implication in renal cell carcinoma (RCC), an angiogenesis-dependent tumor, remains unknown. In the present study, we investigated the role played by VEGI in RCC. The expression of VEGI was examined in human renal tissue and RCC cell lines using immunohistochemical staining and RT-PCR, respectively. The biological impact of modifying the expression of VEGI in RCC cells was evaluated using in vitro and in vivo models. We show that VEGI mRNA is expressed in a wide variety of human RCC cell lines, all of normal renal and most of RCC tissue specimens. VEGI protein expression was observed in normal renal tubular epithelial cells, but was decreased or absent in RCC specimens, particularly in tumors with high grade. Moreover, forced expression of VEGI led to an inhibition of vascular endothelial tube formation, decrease in the motility and adhesion of RCC cells in vitro. Interestingly, forced expression of VEGI had no bearing on growth, apoptosis and invasive capacity of RCC cells. However, tumor growth was reduced in xenograft models. Immunohistochemical staining showed that microvessel density decreased in VEGI forced expression xenograft tumor samples. Taken together, our findings showed that the expression of VEGI is decreased in RCC, particularly in tumors with higher grade. Together with its inhibitory effect on cellular motility, adhesion, vascular endothelial tube formation and tumor growth in vivo, this suggests that VEGI functions mainly through inhibition of angiogenesis and is a negative regulator of aggressiveness during the development and progression of RCC.
Introduction
Renal cell carcinoma (RCC), which accounts for ~2-3% of all adult malignant neoplasm, is the most lethal of the common urologic cancers (1, 2) . Traditionally, 30-40% of patients with RCC die of their cancer, in contrast to the 20% mortality rates associated with prostate and bladder carcinomas (3, 4) . Over the past three decades, there has been an increase in the detection of renal tumors due to the widespread use of noninvasive imaging techniques such as ultrasound and computed tomography scan in the investigation of various non-specific symptoms (5) . This trend has correlated with an increased proportion of incidentally discovered and localized tumors and with improved 5-year survival rates for patients with this stage of disease (6, 7) . However, other factors must also be at play because Chow and colleagues have documented a steadily increasing mortality rate from RCC per unit population since the 1980s and this was observed in all ethnic and both gerders (3, 8) . It has been reported that the incidence of advanced tumors per unit population has also increased; and the mortality rate per unit population has still been negatively affected (3, (8) (9) (10) . In the European Union and the United States, between 46,000 and 63,000 new cases of RCC are diagnosed annually and ~40% of RCC patients die from RCC-related causes each year (7) . In the treatment of renal cell carcinoma, localized disease is curable by surgery, however, metastatic and locally advanced disease are considerably more difficult to treat (11, 12) . Historically, therapeutic options for metastatic or for locally advanced RCC, primarily cytokine therapy, produced low response rates and considerable toxicity (13, 14) . Moreover, it is well known that RCC is one of the most vascular of cancers as reflected by the distinctive neovascular pattern exhibited on renal angiography. Given the dependence of RCC on angiogenesis and the absence of generally effective forms of systemic therapies, it is not surprising that RCC has been targeted for anti-angiogenic approaches. Targeted agents (such as sorafenib, sunitinib malate, pazopanib, bevacizumab) are now well established for the treatment of patients with advanced or metastatic renal cell carcinoma (7, 15, 16) .
Although the targeted therapy is spread among a variety of new active drugs, so far complete cure is achieved very rarely (17) . Experience has shown that the targeted therapies control tumor growth only temporarily and after a latency period that may vary according to the molecular characteristics of the tumor, the malignancy reappears. Resistance to targeted therapy may be caused by activation of alternative proangiogenic pathways, recruitment of bone marrow-derived proangiogenic cells, increased pericyte coverage of tumor vasculature and enhancement of invasion and metastasis (18) (19) (20) . Additionally, host genomics may adversely affect drug metabolism, leading to poor activity or toxicities. However, there does not appear to be cross-resistance among these therapies and subsequent treatment lines can be beneficial. Therefore, finding a new target for anti-angiogenesis could be helpful for treating advanced and metastatic RCC (16) .
Vascular endothelial growth inhibitor (VEGI) [also known as tumor necrosis factor superfamily member 15 (TNFSF15) and TNF ligand related molecule 1 (TL1)], a natural antiangiogenic factor, was first reported in 1999 from human umbilical vein endothelial cells (21) (22) (23) . The full gene of VEGI is ~17 kb, which consists of four exons and three introns and is mapped to human chromosome 9q32. Three splicing variants of VEGI have been reported. Its transcript was found to be expressed in the placenta, lung, kidney, skeletal muscle, pancreas, spleen, small intestine, prostate and colon (23) . The secreted soluble form of VEGI has been demonstrated as a potent anti-angiogenic factor through inhibiting proliferation of endothelial cells (24, 25) . Previous studies have also shown that VEGI expression could significantly reduce motility and adhesion of prostate and bladder cancer cells (26, 27 (23, 28) . Systemic administration of VEGI also markedly inhibited tumor growth and increased survival time in a Lewis lung cancer (LLC) murine tumor model suggesting that pro-apoptotic effect of soluble VEGI in endothelial cells is critical for its antitumor activity (28) (29) (30) (31) (32) .
Despite these observations of VEGI in solid tumors, its role in RCC remains unknown. In the present study, the expression of VEGI was examined in human RCC and normal renal tissues and in RCC cell lines. The biological function of this molecule was investigated in vitro and in vivo, in which the expression of VEGI was manipulated by genetic methods. RNA isolation and reverse transcription PCR. RNA was isolated using Total RNA Isolation reagent (ABgene, Epsom, UK). First strand cDNA was synthesized from 0.5 µg RNA using a reverse transcription kit (Sigma, Poole, Dorset, UK). The quality of cDNA was verified through the amplification and detection of the GAPDH housekeeping gene. VEGI forward and reverse primers (Table I) were designed based on the human VEGI sequence (GeneBank accession no. BD131562). PCR was performed in a GeneAmp PCR system 2400 thermocycler (Perkin-Elmer, Norwalk, CT, USA). Conditions for PCR were 40 sec at 94˚C, 60 sec at 55˚C, 60 sec at 72˚C (35 cycles). PCR products were separated on a 1.4% agarose gel.
Materials and methods

Materials
IHC staining of human renal and xenograft tumor specimens.
Frozen specimens of renal cell carcinoma (n=23), normal renal tissue (n=23) and xenograft tumors (n=24) were cut at a thickness of 6 µm using a cryostat (Leica CM 1900, Leica Microsystems UK Ltd., Buckinghamshire, UK). The nature of the samples was independently verified by two pathologists. After fixation, the sections were blocked with horse serum and probed with or without VEGI antibody (SC-53975) for 1 h. The secondary biotinylated antibody and the avidin-biotin complex were subsequently applied to detect VEGI expression in accordance with the Vectastain Universal Elite ABC kit protocol (Vector Laboratories, Peterborough, UK). After developing color with DAB, the sections were counterstained with Gill's hematoxylin. Staining was independently assessed by the authors. The monoclonal mouse anti-human-VEGI and anti-human-VEGFR2 antibodies were purchased from LSBio Inc. (LS-C76815 and LS-C92359, respectively, LSBio Inc., Seattle, WA, USA). Monoclonal mouse anti-human-Ki67 and anti-human-CD31 (PECAM) antibodies were purchased from Santa Cruz Biotechnology, Inc. (SC-56320 and SC-133091 respectively, Santa Cruz, CA, USA).
Western blot analysis of VEGI expression. Protein concentration in cell lysates were determined using the DC Protein Assay kit (Bio-Rad) and an ELx800 spectrophotometer (Bio-Tek™). Equal amount of proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto nitrocellulose sheets. Proteins were then probed with the VEGI antibody (1:1,500) and peroxidase-conjugated secondary antibodies. Monoclonal mouse anti-human-β-actin (1:1,000, SC-130301, Santa Cruz) was used as a housekeeping control. Protein bands were visualized using the Supersignal™ West Dura system (Pierce Biotechnology, Inc., Rockford, IL, USA) and photographed using an UVITech imager (UVITech, Inc., Cambridge, UK).
Construction of VEGI expressing and ribosome transgenes and transfection.
The full-length human VEGI coding sequence and hammer-head ribozymes targeting human VEGI was cloned into a mammalian expression plasmid vector (pEF/His TOPO TA, Invitrogen, Inc., Paisley, UK). Full primer sequences are provided in Table I . The recombinant plasmid vectors were transformed into chemically competent TOP10 E. coli (Invitrogen). After verification and amplification, empty control plasmids or plasmids containing VEGI expression sequence or ribozyme transgenes were then transfected into 786-O, SW-13 and SC-OR-2 cells using electroporation (Easyjet, EquiBio Ltd., Kent, UK). After selection with blasticidin, the transfectants were used used for subsequent analysis.
Real-time quantitative polymerase chain reaction (qPCR).
Real-time quantitative PCR was carried out using the iCycler iQ5 system (Bio-Rad, Hemel Hemstead, UK) to determine the level of expression of the VEGI transcripts in the cell lines. GAPDH was used as a housekeeping control.
Cell growth assay. This was based on a method we previously described (33) . Briefly, cells were plated into a 96-well plate (2,500 cells/well). Cell growth was assessed after 1, 3 and 5 days. Crystal violet was used to stain cells and absorbance was determined at a wavelength of 540 nm using a spectrophotometer (Bio-Tek, Elx800, UK).
Flow cytometric analysis of apoptosis. All cells including those floating in the culture medium were harvested after a period of incubation. The apoptotic population of the cells was determined using Vybrant ® Apoptosis Assay kit (Invitrogen) and flow cytometry (CyFlow ® SL, Partec GmbH, Münster, Germany).
Wounding assay. The migration of cells in a monolayer across a wounded surface of a near-confluent cell monolayer was examined. Cells at a density of 50,000/well were seeded into a chamber slide and allowed to reach near confluence. The monolayer of cells was then scraped with a fine gauge needle to create a wound of ~200 µm. The movement of cells to close the wound was recorded using a time lapse video recorder and analysed using the motion analysis feature of the Image J software (NIH, USA).
Motility assay using Cytodex-2 beads. Cells (1x10 6 ) were incubated with 100 µl of cytocarrier beads overnight. The beads were washed twice to remove dead cells and then resuspended. Beads/cells (100 µl) were transferred into each well of a 24-well plate. After incubation for 4 h, the cells were fixed in 4% formalin and stained with 0.5% crystal violet before counting.
Invasion assay. This was modified from a method we prevously described (33) . Transwell inserts with 8-µm pore Table I . Primer sequences for PCR.
Primer
Forward Reverse
Primers for T7F: TAATACGACTCACTATAGGG BGHR: TAGAAGGCACAGTCGAGG detecting plasmid Primers to RBTPF: CTGATGAGTCCGTGAGGACGAA RBBMR: TTCGTCCTCACGGACTCATCAG detect ribozymes size were coated with 50 µg Matrigel (BD Matrigel™ basement membrane matrix) and air-dried. After rehydration, 20,000 cells were added to each well. After 96 h cells that had migrated through the matrix to the other side of the insert were fixed, stained and then counted under a microscope.
Cell-matrix adhesion assay. Cell-matrix adhesion was assessed in a standard manner. Cells (40,000) were added in each well of 96-well plate, previously coated with Matrigel (5 µg/well). After 40 min of incubation, non-adherent cells were washed off using BSS buffer. The remaining adherent cells were then fixed and stained with crystal violet. The number of adherent cells was then counted.
Endothelial cell differentiation assay: tube formation on Matrigel (34) . This was based on a Matrigel-sandwich tubule forming assay developed in our laboratory. Briefly, 200 µg of cold Matrigel solution dispersed in 100 µl (Becton-Dickinson, Bristol, UK) was added to a 96-well plate and allowed to air-dry at 37˚C. Following rehydration of Matrigel, it formed a thin bottom layer. HUVEC cells (2.5x10 4 ) per well were seeded onto a 96-well plate and allowed to attach to the bottom of the well (4-6 h). After that, 200 µg of cold Matrigel solution dispersed in 100 µl was loaded to each well again, followed by incubation at 37˚C for 3 h when the second layer of Matrigel solidified. Finally, 10,000 tested cells (different renal cell carcinoma cell lines) were added and incubated at 37˚C in a humidified chamber with 5% CO 2 . Following incubation for 7 or 20 h, cultures were observed and photographed (Nikon, Tokyo, Japan). Group and 786-O VEGIexp4 Group). Each mouse was inoculated subcutaneously at the right flank with 786-O cells (5x10 6 ) in 0.1 ml of PBS for tumor development. The mice were kept in individually ventilated cage (IVC) systems at constant temperature and humidity with 4 animals in each cage. The date of tumor cell inoculation was denoted as day 0. The data of tumor growth and normal behavior such as mobility, visual estimation of food and water consumption, body weight gain/ loss (body weights were measured twice weekly), eye/hair matting and any other abnormal effect were collected every three days. Tumor sizes were measured each three days in two dimensions using a caliper and the volume was expressed in mm 3 using the formula: V = 0.5 a x b 2 where a and b were the long and short diameters of the tumor, respectively.
Tumor xenografts in
Statistical analysis and software. The mean optical density (MOD) feature of RT-PCR and western blot analysis was analysed using software package Image-Pro Plus 6.0 (Media Cybernetics, USA). The method was as follows: every image prepared for comparison was changed to grayscale image. Then, selecting ten points in the comparison region randomly, the MOD of the point was analyzed using the software. The length of cell migration and HUVEC was measured by software Image J (NIH). The distance of HUVEC cells was calculated along the long axes in each compared image.
All statistical analysis was performed using the SPSS 16.0 software. Two sample t-tests was used for normally distributed data. Fisher's exact test was used for analyzing immunohistochemical staining in renal tissues. Differences were considered to be statistically significant at P<0.05.
Results
The expression of VEGI in renal cell carcinoma cell lines and renal tissues. The expression of VEGI was examined in four renal cell carcinoma cell lines, adrenal gland cell line and human renal tissues using conventional RT-PCR. VEGI transcript was detectable in all five cell lines (Fig. 1A) . It was also detected more frequently in normal renal tissues (23/23) than that in renal cell carcinoma tissues (15/23), P<0.01 (Fig. 1B) . Moreover, the expression of VEGI transcript was stronger in normal renal tissues (MOD=0.87±0.13) than that in renal cell carcinoma tissues (MOD=0.24±0.17), P<0.01. Furthermore, in immunohistochemical staining, VEGI was seen in normal renal tubular epithelia cells, but the staining was decreased or absent in renal cell carcinoma cells, particularly in the specimen with higher grade (Fig. 1C) (Fig. 2A) (Fig. 2B) . Comparing with controls, an increase in the VEGI protein level was also seen in 786-O VEGIexp4 cells in western blot analysis (Fig. 2C) . However, there was no significant difference in VEGI protein level between SW-13
VEGIexp4 and OS-RC-2 VEGIexp4 cells and their controls. Therefore, we chose the 786-O cell lines to perform our following test.
Manipulation of VEGI expression had no impact on growth, apoptosis and invasiveness of RCC cells.
First, we examined the effect on growth, apoptosis and invasiveness of 786-O cell lines by VEGI. The growth (Fig. 3A) and invasion (Fig. 3B) (Fig. 3C) . (Fig. 4A) .
In the cytocarrier based cell motility assay, we found that cell motility was reduced significantly in 786-O VEGIexp4 cells. (Fig. 4B) (both P<0.01) . To further investigate the effect of forced expression of VEGI on cell motility, wounding assay was used. We also found that the motility was cient ductibility. However, when HUVECs with 786-O VEGIexp4 co-cultured, the tube formation decreased significantly in comparison with controls (Fig. 4D) (Fig. 5B ).
Discussion
VEGI, first identified from human umbilical vein endothelial cells is known to exist abundantly in arterial endothelial cells (21, 22) . Subsequently, it has been reported that VEGI is also expressed in a wide variety of human cancer cell lines, including breast, prostate, bladder, colorectal and liver (24, (35) (36) (37) (38) . The role of VEGI in human cancer cells has been investigated. According to the literature, it is able to induce apoptosis in endothelial cells via an autocrine pathway (22) (23) (24) (25) . Overexpression of VEGI has been shown to inhibit tumor neovascularisation and progression in cellular and animal models. Chew et al reported that overexpression of VEGI induced apoptosis in endothelial cells and inhibited the growth of xenograft tumors, together with a reduction in the microvessel density (24) . Zhai et al found that the recombinant VEGI protein could markedly inhibit the growth of breast and colon xenograft tumors and suggested that the effect may be through an indirect inhibition on capillary-like structures and cells growth (23 (41) . Overall, the above evidence indicated that the antitumor activity of VEGI is more likely to be the result of an interference with the development of tumor associated vasculature. However, many reports have also suggested that VEGI may inhibit the growth of some human tumor cell lines, including human histiocytic lymphomas (U-937), human breast carcinomas (MCF-7), human epithelial carcinoma (HeLa) and human myeloid lymphomas ML-1a (28, 42) . Our previous results also show that the overexpression of VEGI can directly affect the motility and adhesion of urothelial tumor and prostate cancer cells (26, 27) . Given the dependence of RCC on angiogenesis and the mechanisms of target therapy, it is speculated that VEGI may be an effective target in treating RCC. The present study demonstrated exciting evidence supporting our hypothesis.
First of all, VEGI mRNA was expressed in a wide variety of human RCC cell lines, all the normal renal specimens and a proportion of the RCC specimens. It is obviously that VEGI transcript expression is at lower level in RCC tissues than that in normal renal tissues. The immunohistochemical analysis clearly indicates a similar trend. VEGI protein was found to be expressed at lower level in RCC tissues than that in normal renal tissues and was almost absent in tumors with high grade. The absence or reduction of tumor VEGI expression suggests that there may be a shift in the balance between pro-and anti-angiogenic stimuli. This loss of balance may subsequently produce a microenvironment that is conducive to tumor growth and survival.
Moreover, our results confirm that forced-expression of VEGI was able to directly affect the motility and adhesion of 786-O cells. The number of adherent cells in VEGI forced-expression cells was >50% decreased compared with the wild-type cells. The average distance of VEGI expression cells was also decreased dramatically compared with controls. Therefore, VEGI can directly reduce aggressiveness of renal cancer cells, which is in line with the decreased expression of VEGI in RCC specimens.
Our results demonstrated that force expression VEGI suppressed renal cell carcinoma growth in vivo. Comparing with controls, tumor volume was reduced >50% in the group of BALB/c nude mice injected with 786-O VEGIexp4 cells. However, manipulation of VEGI expression had no impact on growth, or apoptosis of RCC cells in vitro. Combined with the result of endothelial cell differentiation assay (tube formation on Matrigel), when HUVECs with 786-O VEGIexp4 were co-cultured, the tube formation decreased significantly in comparison with controls. As indicated by reduced CD31 staining, significant reduction in microvessel density was observed in xenograft tumor samples. All the above suggested that the anti-RCC growth in vivo of force expression VEGI is more likely to be the result of an interference with the development of tumor associated vasculature than that of a direct effect on tumor cells.
The present study also shows that Ki67 and VEGFR2 protein level was decreased significantly in 786-O VEGIexp4 tumors. It is well known that the Ki-67 protein (also known as MKI67) is a cellular marker for proliferation (43) (44) (45) . Its high expression may be independently associated with an increased risk of poor disease-free survival for many tumors. Its decrease shows that 786-O VEGIexp4 cell proliferation was inhibited in vivo. Probably, this kind of inhibition was also dependent on suppressed vasculogenesis. The VEGF/ VEGFR2 pathway plays a central role in tumor vasculature. Blocking it may achieve inhibition of the growth and metastasis of RCC (46, 47) . VEGFR2 protein level decreased in 786-O VEGIexp4 tumors indicating that VEGI suppressed angiogenesis through VEGF/VEGFR2 pathway except for DR3, SAPK/JNK and p38 MAPK and caspase pathway (48, 49) . This is a new pathway of VEGI to suppress angiogenesis not reported before. It is suggested that reducing tumor neovascularisation and tumor cell proliferation rate may be the reason for VEGI suppressing tumor growth in the xenograft model.
In conclusion, the present study shows that VEGI expression is decreased in renal cell carcinoma, particularly in tumors with higher grade. VEGI, a potential cell migration and adhesion regulating protein of TNFSF, suppressed tumor growth in vivo. This is likely via its inhibitory role on antiangiogenesis, cell migration and adhesion. Our results suggest that VEGI may be a putative tumor suppressor and a potential therapeutic target for RCC.
